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Abstract. A current need in the global effort to eliminate lymphatic ﬁlariasis (LF) is the availability of reliable diagnostic
tools that canbeused to guideprogrammatic decisions, especially decisionsmade in the ﬁnal stages of the program. This
study conducted in The Gambia aimed to assess antiﬁlarial antibody levels among populations living in historically highly
LF-endemic areas and to evaluate the use of serologic tools to conﬁrm the interruption of LF transmission. A total of 2,612
dried blood spots (DBSs) collected from individuals aged 1 year and above from 15 villages were tested for antibodies to
Wb123 by enzyme-linked immunosorbent assay (ELISA). A subset of DBS (N = 599) was also tested for antibodies to
Bm14 by ELISA. Overall, the prevalence of Wb123 was low (1.5%, 95% conﬁdence interval [CI] 1.1–2.1%). In 7 of
15 villages (46.7%), there were no Wb123-positive individuals identiﬁed. Individuals with positive responses to Wb123
ranged in age from 3 to 100 years. Overall, Bm14 prevalencewas also low (1.5%, 95%CI 0.7–2.8%). Bm14 positivity was
signiﬁcantly associated with older age (P < 0.001). The low levels of antibody responses toWb123 observed in our study
strongly suggest that sustainable LF transmission has likely ceased in The Gambia. In addition, our results support the
conclusion that serologic tools can have a role in guiding programmatic decision making and supporting surveillance.
INTRODUCTION
Lymphatic ﬁlariasis (LF) is a mosquito-transmitted parasitic
disease caused by three main species of ﬁlarial worms
(Wuchereria bancrofti, Brugia malayi, and B. timori).1 In 1997,
at the 50th World Health Assembly (WHA), a resolution was
passed to eliminate LF as a public health problem by 2020
(WHA resolution50.29).2Shortly thereafter, in 2000, theGlobal
Program to Eliminate Lymphatic Filariasis (GPELF) was or-
ganized to assist countries in achieving this goal.3 At the onset
of GPELF, it was estimated that 120 million individuals were
infected and that approximately 1.3 billion people throughout
the tropics and subtropics were at risk of ﬁlarial infection.3
To reach the established elimination targets, LF programs set
out to treat individuals in endemic areas through annual
community-wide mass drug administration (MDA) for at least
5 years. By the end of 2015, MDA had been implemented in
63 of 73 LF-endemic countries, with a cumulative total of
6.2 billion treatments delivered since the launch of GPELF.4
Typically, LF programs ﬁrst conduct mapping surveys to
identify areas to target for treatment, then conduct multiple
rounds of MDA, and ﬁnally conduct transmission assessment
surveys (TAS) designed to determine whether infection levels
are low enough to stop MDA.5 Although most LF-endemic
countries have successfully followed this approach, some
countries have yet to scale-up programmatic activities. Al-
though there is a clear need to implement MDA in some of
these areas, others have a history of high microﬁlariae (mf)
prevalence; but recent surveys have failed to conﬁrm the
presence of infection and appropriate programmatic action is
unclear. A current need in theglobal effort to eliminate LF is the
availability of reliable diagnostic tools that can be used to
guide programmatic decisions, especially decisions made in
the ﬁnal stages of the program. In addition, validated tools
are needed to conﬁrm the absence of LF transmission in
situations where the requirement for program implementation
is unclear.
In the early stages of the global LF program, detection of mf
in the peripheral blood was used routinely to monitor the im-
pact ofMDA.3,6,7 Inmost LF-endemic areas in theworldwhere
the parasite is nocturnally periodic, logistic challenges were
encountered because of the requirement to collect blood at
night between 22:00 and 02:00 hours. Furthermore, it became
increasingly difﬁcult to detect mf in populations after multiple
rounds of MDA.8 Many of the limitations experienced with mf
detection were addressed with the introduction of the immu-
nochromatographic card test (ICT) to detect circulating ﬁlarial
antigen (CFA).9 Importantly, the ICT could be conducted with
blood collected at any time of the day, eliminating the need for
night blood collections. Based on the results of amulticountry
comparison, the ICT was the diagnostic tool recommended
for TAS.8 Currently, the recently introduced Filariasis Test
Strip (FTS)10 is the ofﬁcial diagnostic tool recommended for
TAS. As production of the ICT is being phased out, it is ac-
ceptable for LF programs to use either the ICT or FTS in the
interim.
Although tools to detect CFA have been and continue to be
useful for the global LF program, there are some limitations to
their use. Similar to theobserveddecline inmf prevalence after
treatment, antigenemia also begins to decline and becomes
increasingly difﬁcult to detect in populations that have been
subjected tomultiple rounds ofMDA.8 In addition, as infection
prevalence declines, the prevalence and magnitude of sero-
logic responses shifts, and operational sensitivity of the as-
says will decline compared with the laboratory-deﬁned
sensitivity. Recent evidence suggests that the detection of
antiﬁlarial antibodies provides the earliest indicator of ﬁlarial
exposure,11 and the absence of detectable antibody re-
sponses may provide evidence that transmission has been
interrupted. As control programs move ahead, there will be
fewer infection-speciﬁc antibody responses in populations,
and increasingly, only residual antibody responses in older
individualswill be observed.Many of the currently available LF
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antibody tests have been shown to be sensitive measures of
exposure and infection, but may lack the speciﬁcity needed to
make important programmatic decisions.12–14 However, the
identiﬁcation of a highly speciﬁc recombinant antigen,
Wb123,15 as an early serologic marker for ﬁlarial infection
provides a new surveillance tool16 that may be useful to con-
ﬁrm the interruption of LF transmission.
In the 1950s, mf prevalence in The Gambia was reported to
be approximately 50%,17 among the highest in the world.
Surveys conducted in the 1970s showed that mf prevalence
had declined signiﬁcantly in the absence of any LF-speciﬁc
interventions.18 In 2001, stored serum samples from individ-
uals living in historically highly LF-endemic areas were tested
for the presence of CFA, a more sensitive diagnostic marker
than mf,8 and results indicated an even further decline in LF
prevalence compared with results from the 1970s.19 In 2003,
the Gambian Ministry of Health and Social Welfare (MOHSW)
conducted a national LF mapping survey with the intent of
identifying areas in need of MDA. Interestingly, the results in-
dicated that MDA was not necessary.19 In 2013, the MOHSW
conducted TAS and found no evidence of LF transmission
among young children.19 Although The Gambia has not fol-
lowed the traditional approach for LF elimination, it seems that
the current criteria used as the operational deﬁnition of elimi-
nation have been achieved. The absence of antigenemia
among children was likely an indicator of interrupted trans-
mission, but therewasno information collected fromolder age
groups. In the absence of LF-speciﬁc interventions, the
Gambian MOHSW believed it was important to assess LF
status among older age groups to complement the TAS re-
sults. The current study aimed to assess antiﬁlarial antibody
levels among communities living in historically highly LF-
endemic areas of The Gambia and to use serologic tools to
determine whether interruption of LF transmission has been
achieved.
METHODS
Study site and design. The study took place in February
2015 in The Gambia, a small African country with the Atlantic
Ocean to the west and all of its land borders shared with
Senegal. It is the smallest country on the mainland of the
continent and has an estimated population of 1.9 million
people. The country is divided into ﬁvedivisions (Central River,
Lower River, North Bank, Upper River, and Western) and one
city (Banjul). Fifteen villages (Dampha Kunda, Jappineh,
Jambanjelly, Jiboroh Koto, Kafuta, Kamanka, Kembujeh,
Keneba, Kololi, Latrikunda Sabiji, Mandinaring, Marakissa, Sare
Opatah Jawa/Darsilameh, Sikon Batabu Kantora, and Tamba-
sansang)with thehighesthistoricevidenceofLFwerepurposely
selected for this study. The villages were located in four of the
ﬁve divisions and in Banjul. No villages in the Central River Di-
vision were included in the study because LF prevalence in this
area was low in the 1970s, and no evidence of infection was
found in recent surveys. Following World Health Organization
(WHO) guidance for monitoring LF in sentinel sites,5 a conve-
nience sample of approximately 300 individuals (³ 1 year old) in
each village was enrolled in the study.
Ethical considerations. The study was approved by the
Gambia Government/MRC Joint Ethics Committee. The In-
stitutional Review Board of the U.S. Centers for Disease
Control and Prevention (CDC) determined CDC to be a
nonengaged researchpartner. Studydetailswere explained to
potential participants and written informed consent was
obtained from persons who agreed to participate. Parents
or guardians provided permission for participation of chil-
dren < 18 years. In addition, children aged between 7 and
17 years were asked to provide verbal assent for their partic-
ipation. All identiﬁable information was kept conﬁdential and
maintained using a secure database with access restricted to
essential study personnel.
Data collection.On the day of sample collection, residents
of the community were asked to come to a central location
within the village. On obtaining informed consent, participants
were assigned a unique identiﬁer and asked to provide basic
demographic information such as age and sex. All data were
collected on Android platform smartphones (BLU, Miami, FL)
using the LINKS application20 and uploaded to a secure SQL
server.
Blood collection and antigen testing. Approximately
100 μL of bloodwas collected using a ﬁnger stick and used for
the detection of CFA by ICT (Alere, Scarborough, ME). The
cardswere read at 10minutes andmarked as either positive or
negative according to the manufacturer’s instructions. An
additional 60 μL of blood (10 μL per extension × 6 extensions)
was collected onto the ﬁlter paper (Cellabs, Sydney, Australia)
and dried and stored for antiﬁlarial antibody testing. The dried
blood spots (DBSs) were stored at −20C until shipped to the
CDC for testing.
Antibody testing by enzyme-linked immunosorbent
assay (ELISA). DBSs were tested with the Filaria Detect™
IgG4 ELISA (InBios, Seattle, WA), a direct enzyme immuno-
assay that detects IgG4 antibodies to the recombinantWb123
antigen. This test was performed according to the protocol
provided by the manufacturer with minor modiﬁcations.
Brieﬂy, one blood spot extension (10 μL whole blood) was
eluted overnight in 250 μL of the sample dilution buffer pro-
vided in the kit to yield anapproximate1:50 serumdilution. The
following day, the samples were tested in duplicate by adding
100 μL of eluate to each well. Kit-provided positive and neg-
ative controlswere also tested in duplicate at a 1:50 dilution. In
addition, two internal positive controls (H3, H19; not provided
in the kit) available at the CDC were tested in duplicate
at 1:1,500 (H3) and 1:900 (H19) dilutions, respectively, on
each plate. These internal controls were used to standardize
results across plates. The plates were incubated at 37C for
30 minutes and then washed with the kit-provided wash
buffer. Mouse anti-human IgG4 conjugated with horseradish
peroxidase (HRP) was added to each well at a 1:100 dilution
and incubated at 37C for 30minutes. Afterwashing, 100μLof
tetramethylbenzidine (TMB) was added to each well, and
plates were developed at room temperature in the dark for 9
minutes. Reactions were stopped by adding 50 μL of the kit-
provided stop solution to each well, and plates were read at
450 nm. To compare optical density (OD) values between
Wb123 ELISA plates, mean OD values for each sample were
divided by the mean OD of the H3-positive control to nor-
malize the results.
All available samples from two villages (Kololi and Tam-
bansansang) were tested with a noncommercial ELISA (CDC;
Atlanta, GA) for IgG4 antibodies against the recombinant
Bm14 antigen.21 This assay has relatively high sensitivity
(92%) and speciﬁcity (99%) and was determined to be an
appropriate alternative to a commercially available Bm14
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ELISA.Greinermicrolon high-binding plates (GreinerBio-One,
Monroe, NC) were coated with Bm14 at a concentration
of 0.3 μg/mL in antigen sensitizing buffer (0.5 M Tris/HCl,
pH 8.0 + 0.3 M KCl + 2 mM EDTA) and incubated overnight at
4C. One blood spot extension was added to 250 μL of the
dilution buffer (PBS pH 7.2 + 0.3% Tween20 + 5% milk) and
incubated overnight at 4C. Positive control serum samples
werediluted1:50 in thedilutionbuffer andused toconstruct an
9-point standard curve and to serve as two calibrator positive
controls for each plate. All controls were held at 4Covernight.
The following day, the diluted samples and controls were
tested in duplicate by adding an aliquot of 100 μL to eachwell.
Plates were incubated at room temperature on a shaker for
30 minutes. Mouse anti-human IgG4 conjugated with HRP
(cloneHP6025; Southern Biotech, Birmingham, AL) was di-
luted at 1:2,000 and 100 μL was added to each well. Plates
were incubated at room temperature on a shaker for 30 min-
utes. TMB (100 μL) was added to each well and plates were
developed at room temperature for 2 minutes. One hundred
microliters of 1 M H2SO4 was added to each well to stop the
reaction, and plates were immediately read at 450 nm. Plates
were washed between each step with PBS + 0.3% Tween20.
Cutoff determination for ELISAs. Cutoff values for
Wb123 and Bm14 were calculated at CDC from receiver
operator characteristic curves using sera from W. bancrofti
mf positive patients and presumed negative sera from adult
US citizens with no history of foreign travel to LF-endemic
countries.
Statistical analysis. Statistical analyses were performed in
Stata version 14.1 (StataCorp LP; College Station, TX) and
used the 5% level of signiﬁcance. χ2 tests and logistic re-
gression were used to identify associations between sero-
positivity and other factors.
RESULTS
A total of 4,481 individuals (aged 1–100 years) from the 15
villages were enrolled in the study. Of those enrolled, a total of
2,612 (58.2%) DBS from all the 15 villages were tested for
antibodies to Wb123. There was no difference in age or sex
between individuals not included for serologic testing and
individuals with antibody results. Demographic information
was not available for 161 (6.2%) samples with antibody re-
sults. Antibody prevalence for individuals with missing de-
mographic data was not different from prevalence for those
with available demographic information. There were no indi-
viduals who were antigen positive by ICT. Overall, the preva-
lence of positive Wb123 responses was low (1.5%, 95%
conﬁdence interval [CI] 1.1–2.1%). In 7 of 15 villages (46.7%),
there were no antibody-positive individuals identiﬁed. Of the
eight villages with at least one person with a positive Wb123
result, six (75%)were located in theWestern Division (Figure 1).
Individuals with positive responses to Wb123 ranged in age
FIGURE 1. Location of the 15 study villages in The Gambia and Wb123 antibody status in 2015. This ﬁgure appears in color at www.ajtmh.org.
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from 3 to 100 years. Wb123 results by community are sum-
marized in Table 1. There was no statistically signiﬁcant differ-
ence in Wb123 prevalence among the study villages once
adjusted for age, sex, and clustering by village.
All available samples from Kololi and Tambasansang were
also tested by Bm14 ELISA. Overall, Bm14 prevalence was
low (1.5%, 95% CI 0.7–2.8%) in these two villages. In Kololi,
there were twoWb123-positive individuals, but there were no
positive Bm14 responses in this community. In Tamba-
sansang, there were 10 (3.4%) Wb123-positive individuals
ranging in age from4 to 65 years. Although a similar number of
Bm14positive personswas identiﬁed (9/292; 3.1%), all Bm14-
positive individuals were older than 50 years. Bm14 positivity
was signiﬁcantly associated with older age (P < 0.001). The
results of antibody testing and historic mf results are sum-
marized in Table 2.
DISCUSSION
The results of TAS conducted in 2013 in The Gambia in-
dicated that there was no LF transmission among 6- and
7-year-old children, and in 2016, The Gambia was removed
from the WHO’s ofﬁcial list of LF-endemic countries.4 Al-
though the absence of antigenemia among children in The
Gambia was likely an indicator of interrupted transmission,
therewas no information collected fromolder age groups. Our
study aimed to assess antiﬁlarial antibody levels among
populations living in historically highly LF-endemic areas in
The Gambia and to evaluate the use of serologic tools to
conﬁrm the absence of LF transmission.
Overall, no antigenemia was detected, and the prevalence
of antibodies to Wb123 was low in the 15 villages included in
the survey conducted in 2015. Although there was clear evi-
dence of LF transmission in the 1970s,18 results from the
current survey suggest that little to no transmission of LF was
occurring in these areas, consistent with the results of TAS
implemented in The Gambia in 2013. The dramatic decline in
LF prevalence over a 50-year period has been observed with
increasingly sensitive diagnostic markers and strongly sug-
gests that sustainable LF transmission likely ceased in The
Gambia during this period. The decrease in LF prevalence has
been mainly attributed to a reduction in mosquito density
because of changes in climate, improved standard of living,
and the use of bednets for protection from mosquito bites
because no LF-speciﬁc interventions have taken place.18 The
rapid scale-up of insecticide-treated nets used for malaria
control since 2000 has likely further contributed to the
decline.22,23 Antibody responses are generally considered an
early and sensitive indicator of transmission, and although
there is incomplete information about the duration of antibody
responses, they do seem to fall as transmission declines. In a
study conducted in the Cook Islands, samples collected in the
mid-1970s were analyzed for antibodies to Wb123 and com-
pared with results from samples collected from the same
island in 1992, 5 years after a single round of MDA against
LF. Results indicated a signiﬁcant decrease in Wb123 anti-
body positivity, suggesting that LF transmission had signiﬁ-
cantly decreased.24Recently, in Indonesia, antibody responses
were used to successfully distinguish areas where pro-
grams had been implemented and successful, suboptimally
TABLE 1
Wb123 antibody prevalence by community in The Gambia in 2015
Division Community Total enrolled Total tested Median age in years (range) Wb123 positive % Positive [95% CI]
Banjul Kololi 335 307 10 (1–70) 2 0.7 [0.1, 2.3]
Banjul Latrikunda Sabiji 305 124 17 (1–70) 0 0.0 [0, 2.9*]
Lower River Jappineh 308 123 10 (1–80) 0 0.0 [0, 3.0*]
Lower River Keneba 305 124 10 (1–80) 0 0.0 [0, 2.9*]
North Bank Sare Opatah Jawa/Darsilameh 309 118 11 (1–90) 0 0.0 [0, 3.1]
Upper River Dampha Kunda 342 124 8 (1–89) 0 0.0 [0, 2.9*]
Upper River Tambasansang 294 292 12 (1–100) 10 3.4 [1.7, 6.2]
Western Jambanjelly 235 90 11 (1–70) 1 1.1 [0, 6.0]
Western Jiboro Koto 231 90 11 (1–70) 3 3.3 [0.7, 9.4]
Western Kafuta 305 124 9.5 (1–70) 0 0.0 [0, 2.9]
Western Kamanka 305 123 12 (2–80) 0 0.0 [0, 3.0]
Western Kembujeh 303 125 10 (1–80) 4 3.2 [0.9, 8.0]
Western Mandinaring 299 296 10.5 (1–100) 12 4.1 [2.1, 7.0]
Western Marakissa 302 275 6 (1–90) 4 1.5 [0.4, 3.7]
Western Sikon Batabu Kantora 303 116 13 (1–90) 1 0.9 [0, 4.7]
#N/A (missing demographic
data)
– – 161 N/A 3 1.9 [0.4, 5.3]
– Total 4,481 2,612 11 (1–100) 40 1.5 [1.1, 2.1]
*One-sided, 97.5% conﬁdence interval.
TABLE 2
Microﬁlariae prevalence in selected villages of TheGambia in the 1970s18 and antiﬁlarial responses toWb123andBm14 in the samevillages in 2015
Kololi Tambasansang
1974–1976 2015 1974–1976 2015
Age n Mf [95% CI] n Wb123 [95% CI] Bm14 [95% CI) n Mf [95% CI] n Wb123 [95% CI] Bm14 [95% CI]
0–5 N/A – 52 0.0 [0, 6.8*] 0.0 [0, 6.8*] N/A – 61 3.3 [0.4, 11.3] 0.0 [0, 5.9*]
6–15 44 22.7 [11.5, 37.8] 169 1.2 [1.4, 4.2] 0.0 [0, 2.2] 107 17.8 [11.0, 26.3] 121 2.5 [0.5, 7.1] 0.0 [0, 3.0]
16+ 38 26.3 [13.4, 43.1] 86 0.0 [0, 4.2*] 0.0 [0, 4.2] 66 25.8 [15.8, 38.0] 110 4.5 [1.5, 10.3] 8.2 [3.8, 15.0]
*One-sided, 97.5% conﬁdence interval.
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implemented, and not implemented at all.25 Although there is
a need to gain more practical experience to operationalize
the use of antibody assays, including determining the most
appropriate diagnostic platform (e.g., rapid test, ELISA), our
results have added information on the utility of serologic
tools in an area where MDA was never conducted.
Although seroprevalence was low, positive responses were
notcompletely absent.Antibody responsescould representvery
focal areas of persistent or recurrent LF transmission, residual
seropositivity after interruption of transmission, cross-reactivity,
or false-positive results; the detected Wb123 responses may
have different implications than the detected responses to
Bm14. Approximately, half of the villages had at least one posi-
tive Wb123 response. Six of the eight villages with at least one
antibody-positive individual were located in the Western Di-
vision, where mf rates were in excess of 50% in the 1950s.17
However, the absence of positive antigen tests in these villages
makes it less likely that these results reﬂect focal transmission.
If positive serology reﬂected persistence after the inter-
ruption of transmission, an association with age would be
expected.8,26,27Antibodies toBm14canpersist for years,but the
expectation is that seroreversion will occur at some point.28,29
However, currently, there is insufﬁcient data available on the
rates of antibody decay to accurately predict when ﬁlarial
infection cleared. An association between seropositivity and
age was seen for the responses to Bm14, but not to Wb123;
in Tambasansang, Bm14-positive individuals were all older
than 50 years and could have been exposed to infected
mosquitoes before transmission had ceased in the country.
The recombinant Bm14 antigen has also been reported as a
highly sensitivemarker for the assessment of ﬁlarial antibodies,
but it is also known to cross-react with closely related ﬁlarial
parasites.13,14 Wb123, used on various diagnostic platforms
including ELISAs, is reported to have high sensitivity and
speciﬁcity for distinguishingW. bancrofti infection from closely
related ﬁlarial infections.15 However, a possible explanation for
the detected positiveWb123 responses is lower than expected
Wb123 speciﬁcity. It is possible that the cutoff values for the
ELISAs were inaccurate. The ability to deﬁne robust cutoffs for
serological assayscanbechallengingand isoften limitedby the
availability of well-characterized panels of samples to de-
termine appropriate cutoffs.
As the GPELF continues to make progress, it is critical to
identify strategies for reaching stated goals. Our results strongly
suggest that LF transmission has likely ceased in The Gambia
and thatnoprogrammatic intervention is required.Although there
is a clear need to better understand the limitations of current
antibody tests, to develop appropriate sampling strategies, and
todetermineoptimal age groups todeﬁne antibody thresholds to
provide robust evidence of the absence of transmission, our re-
sults also support the use of antibody tools to determine the
status of LF transmission and suggest that serologic tools can
have a role in guiding programmatic decision making.
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